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OBJECTIVES We sought to compare coronary stent implantation with balloon angioplasty (BA), in a
diabetic population, in terms of the six-month angiographic outcome and four-year clinical
events.
BACKGROUND Diabetic patients have a poor angiographic and clinical outcome after standard coronary BA.
To date, it is still unclear whether stent implantation may improve this outcome.
METHODS We investigated this issue by individual matching of 314 diabetic patients treated with either
coronary stenting or standard BA. These two groups were derived from a population of
consecutive diabetic patients (1993 to 1996). Matching criteria were gender, anti-diabetic
regimen, stenosis location, reference diameter, and minimal luminal diameter (0.4 mm).
One lesion per patient was considered for matching.
RESULTS Baseline characteristics were similar between the two groups of 157 patients. At six months,
the rates of restenosis (27% vs. 62%; p 0.0001) and occlusion (4% vs. 13%; p 0.005) were
lower in the stent group than in the BA group. This was associated with a significant decrease
in ejection fraction at six months in the BA group (p  0.02) while, during the same period,
no change was observed in the stent group (p  NS). Subgroup analysis demonstrated that
angiographic benefit was consistent among the subgroups. At four years, the combined
clinical end point of cardiac death and non-fatal myocardial infarction was lower in the stent
group (14.8% vs. 26.0%; p  0.02), as was the need for repeat revascularization (35.4% vs.
52.1%; p  0.001).
CONCLUSIONS In a population of diabetic patients, coronary stent implantation was associated with a highly
beneficial effect on the six-month angiographic outcome and four-year clinical events
compared with standard BA. (J Am Coll Cardiol 2002;40:410–7) © 2002 by the American
College of Cardiology Foundation
Diabetics currently comprise 15% to 25% of patients re-
ferred for coronary revascularization (1–4). Several studies
reporting a high rate of cardiac events in diabetics treated-
with standard balloon angioplasty (BA) (1,2,5–7) have
See page 424
generated concern regarding the use of percutaneous coro-
nary revascularization (PCR) in this group of patients and
have led to a general consensus that surgical revasculariza-
tion may be preferable in this population (8).
It is now well established that diabetics have unacceptably
high rates of restenosis (60%) after coronary BA (4,9,10),
and more recent studies have shown dramatically higher
rates of occlusive restenosis (13% to 14%) in diabetics than
in non-diabetics (4,9). Recent studies investigating the
effect of diabetes on restenosis after coronary stenting
(11–14) have reported a more favorable angiographic outcome
after stenting, although the degree of restenosis rates varied
markedly among the studies (24% to 55%). The marked
discrepancies between these study groups from different pop-
ulations has led to continuing uncertainty regarding the po-
tential beneficial effect of stent implantation on both the
angiographic and clinical outcome in diabetic patients.
Thus, we designed our study to investigate the impact of
coronary stenting on restenosis, late vessel occlusion, left
ventricular (LV) function, and long-term clinical outcome
in diabetic patients. These issues were investigated by
individual matching of a consecutive series of diabetic
patients treated with coronary stenting to a consecutive
series of diabetics treated with BA.
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METHODS
Stent and BA groups. We identified, from the records of
our catheterization laboratory (1993 to 1996), 164 consec-
utive diabetic patients who underwent coronary stent im-
plantation during a percutaneous transluminal coronary
angioplasty (PTCA) procedure and 462 who underwent
standard BA without adjunctive stent implantation.
All patients in whom the procedure was considered
successful by the operator were included. Patients undergo-
ing primary, rescue BA for acute myocardial infarction (MI)
or rescue stent implantation for occlusive dissection were
not included.
At the time of the initial procedure, the patients were
asked to return for follow-up angiography at six months,
regardless of their symptomatic status. Angiography was
performed earlier if there was a clinical indication. Angio-
graphic follow-up was actually performed in 138 patients
(84%) in the stent group and in 377 patients (82%) in the
BA group.
Matching process. In order to compare the results of
coronary stenting and BA, 157 diabetic patients from the
stent group were individually matched to 157 patients from
the BA group; the matching characteristics were gender,
anti-diabetic regimen, target lesion location, reference di-
ameter (within 0.4 mm), and minimal luminal diameter
(MLD; within 0.4 mm). Only one lesion per patient was
considered for matching. At the end of the matching
process, no suitable match was found for seven patients in
the stent group. The matching process was performed by
two investigators who were unaware of the angiographic and
clinical outcomes of the patients.
Definition of diabetes mellitus. At the time of the initial
procedure, patients were classified as diabetic if they were
treated with oral hypoglycemic drugs or insulin or if they
had a history, as documented in their medical records, of
elevated (140 mg/dl) fasting blood glucose on at least two
separate occasions in conjunction with ongoing dietary
measures. They were classified in three categories depend-
ing on the anti-diabetic management at the time of the
initial procedure: 1) diet alone; 2) oral hypoglycemic drugs
(diet and oral hypoglycemic drugs but no insulin); and 3)
insulin (irrespective of other therapy).
Baseline blood glucose and creatinine levels, as well as the
presence of other organ damage (e.g., retinopathy, nephrop-
athy, neuropathy), as documented in the medical records,
were recorded.
Angioplasty procedure. Balloon angioplasty and coronary
stenting were performed according to the standard tech-
nique in our laboratory (4,12). All patients received 300
mg/day of aspirin, and a bolus dose of heparin (10,000 IU)
was administered just before PTCA. Patients who had
conventional BA received aspirin alone, whereas patients
who had coronary stent implantation received a combina-
tion of aspirin (325 mg/day) and ticlopidine (500 mg/day)
for four to six weeks and then aspirin alone. None of the
patients was treated with glycoprotein IIb/IIIa inhibitors.
Angiographic analyses. Qualitative analyses were per-
formed independently by two experienced interventional
cardiologists. Lesions were classified in accordance with the
American Heart Association/American College of Cardiol-
ogy classification, as modified by Ellis and colleagues (15).
Anterograde blood flow was graded using the Thrombolysis
in Myocardial Infarction (TIMI) trial classification (16).
Quantitative computer-assisted angiographic measure-
ments were obtained, as previously described, from end-
diastolic frames at maximal dilation, using the computer-
assisted evaluation of stenosis and restenosis (CAESAR)
system (4,12). The following definitions were used: “acute
gain” was defined as the MLD after the index procedure,
minus the MLD before the procedure; “late loss” was
defined as the MLD after the index procedure, minus the
MLD at follow-up; “net gain” was defined as the difference
between acute gain and late loss; “restenosis” was defined as
50% diameter stenosis at follow-up; and finally, “complete
vessel occlusion” was defined as TIMI flow grade 0 or 1.
The left ventricular ejection fraction (LVEF) was calcu-
lated on ventriculograms obtained before angioplasty and at
follow-up.
Clinical follow-up. Long-term clinical follow-up begin-
ning at the time of the index procedure was accomplished by
a questionnaire completed by the patient or by telephone
contact. Review of hospital records and contact with the
referring physician enabled us to complete some missing
information. The information obtained included the occur-
rence of MI since the initial PTCA procedure, subsequent
need for additional revascularization, and death (cardiac or
non-cardiac). Sudden death and death of unknown cause
were classified as cardiac deaths. Clinical follow-up was
obtained in all patients at an average of 3.8  1.3 years.
Statistical analysis. Data are presented as the mean value
 SD. Comparisons between groups for continuous data
were performed with the paired or unpaired Student t test.
Differences between proportions were assessed by chi-
square analysis. Survival without an event was estimated
using the Kaplan-Meier method. Differences were tested
using the log-rank test. Multivariate correlates of events
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ARTS  Arterial Revascularization Therapy Study
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were analyzed using the Cox proportional hazards model. A
value of p  0.05 was considered to indicate statistical
significance.
RESULTS
Baseline characteristics. The adequacy of the matching
process was confirmed by the lack of difference between the
groups with respect to major baseline patient and lesion
characteristics (Tables 1 and 2). Most of the 314 diabetics
were male (76%; mean age 61  10 years). Twenty-four
percent had a documented complication of diabetes other
than atherosclerosis (e.g., nephropathy, neuropathy, reti-
nopathy). Twenty-six percent of the patients had unstable
angina, and 27% had experienced a recent (1 month) MI.
Eighteen percent of the patients were treated with diet
alone, 68% were treated with oral hypoglycemic drugs, and
14% with insulin.
Percutaneous coronary revascularization was performed
for a recent infarct-related lesion in 24% of cases and for
restenosis in 20% of cases (Table 2). The dilated lesion was
most often located in the left anterior descending coronary
artery (45%) and less frequently in the right coronary artery
(31%), left circumflex coronary artery (19%), or saphenous
vein graft (SVG; 5%). Nineteen percent of the lesions had
TIMI flow grade 3.
In the stent group, a single stent was implanted in 80% of
cases; the most frequently used stent was the Palmaz-Schatz
(65%). The maximal balloon size was 3.2  0.4 mm, and
the maximal inflation pressure was 15  3 atm.
Angiographic outcome. Angiographic follow-up was ob-
tained in 134 patients in the BA group (85%) and in 133
patients in the stent group (85%). The results of quantitative
angiography are presented in Table 3. The immediate
angiographic outcome was significantly better in stented
patients (MLD; 2.70  0.46 mm) than in BA patients
(MLD; 1.99  0.47 mm) (p  0.0001). At follow-up
angiography, patients in the stent group had a larger net
gain (1.08  0.82 vs. 0.47  0.73 mm; p  0.0001) and
thus a significantly greater MLD at follow-up (1.81  0.83
vs. 1.20  0.76 mm; p  0.0001). When analyzed by the
categorical approach with 50% diameter stenosis as the
criterion for restenosis, 27% of the stent group and 62% of








(n  157) p Value
Age (yrs) 61  10 62  9 61  11 0.63
Males 240 (76%) 120 (76%) 120 (76%) 1
Smokers 154 (49%) 75 (48%) 79 (50%) 0.65
Hypertension 196 (62%) 104 (66%) 92 (59%) 0.42
Hypercholesterolemia 142 (45%) 76 (49%) 66 (43%) 0.26
Family history of CAD medications 132 (42) 61 (39) 71 (45) 0.26
Oral antiplatelet drugs 313 (99%) 156 (99%) 157 (100%) 0.99
Beta-blockers 229 (73%) 118 (75%) 111 (70%) 0.45
Calcium channel antagonists 96 (31%) 45 (29%) 51 (32%) 0.54
ACE inhibitors 141 (31%) 71 (45%) 70 (45%) 0.99
Lipid-lowering agents 140 (45%) 71 (45%) 69 (44%) 0.91
Statins 111 (35%) 52 (33%) 59 (38%) 0.48
Fibrates 30 (9%) 19 (12%) 11 (7%) 0.18
Antidiabetic management
Diet alone 58 (18%) 29 (18%) 29 (18%)
Oral hypoglycemic drugs 214 (68%) 107 (68%) 107 (68%) 1
Insulin 42 (14%) 21 (14%) 21 (14%)
Glucose (mmol/l) 9.00  3.39 8.94  3.17 9.06  3.61 0.78
Creatinine (mol/l) 97  39 101  49 94  27 0.21
End-organ damage
Retinopathy 27 (9%) 15 (10%) 12 (8%) 0.55
Nephropathy 51 (16%) 25 (16%) 26 (17%) 0.88
Neuropathy 12 (4%) 6 (4%) 6 (4%) 1
At least one of the above 76 (24%) 38 (24%) 38 (24%) 1
Previous PTCA 106 (34%) 58 (37%) 48 (31%) 0.23
Previous CABG 27 (9%) 14 (9%) 13 (8%) 0.84
Recent (1 month) MI 84 (27%) 43 (27%) 41 (26%) 0.80
Unstable angina 82 (26%) 37 (24%) 45 (27%) 0.52
Multiple vessel disease 177 (56%) 86 (55%) 91 (58%) 0.57
No. of dilated vessels 1.20  0.42 1.20  0.42 1.20  0.41 0.89
LVEF (%) 58.6  14.8 58.7  14.3 58.5  15.2 0.78
Data are presented as the mean value  SD or number (%) of patients.
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass graft surgery; CAD  coronary artery disease;
LVEF  left ventricular ejection fraction; MI  myocardial infarction; PTCA  percutaneous transluminal coronary
angioplasty.

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the BA group had restenosis (p  0.0001). Total occlusion
of the dilated site at follow-up occurred in only 4% of the
stent group and in 13% of the BA group (p  0.005).
Subgroup analyses based on the anti-diabetic regimen,
presence of end-organ damage, site of angioplasty, vessel
size, lesion length, or TIMI flow grade at baseline were
performed (data not shown). In each of these subgroups,
stent implantation was associated with a significant reduc-
tion in the rate of restenosis and/or late occlusion. However,
stent implantation in a long lesion or SVG was still
associated with a restenosis rate of 34% to 40%, and stent
implantation in a vessel 3 mm in diameter or with TIMI
flow grade 3 was associated with an occlusion rate of 6%
to 7%.
LV function at angiographic follow-up. Among the 267
patients with angiographic follow-up, 226 (85%) had ven-
triculograms obtained before PTCA and at follow-up that
were suitable for determination of ventricular function.
Total occlusion of the dilated site at follow-up was associ-
ated with a significant decrease in LVEF between baseline
and follow-up (9.9 11.2%; p 0.001) that was not seen
in patients without restenosis or with non-occlusive reste-
Table 3. Quantitative Angiographic Analysis in the 267 Patients With Angiographic Follow-Up
Balloon Angioplasty
Group (n  134)
Stenting Group
(n  133) p Value
Reference diameter (mm)
Before 3.06  0.47 3.06  0.49 0.98
After 3.05  0.49 3.11  0.49 0.32
Follow-up 3.07  0.50 3.07  0.49 0.94
Minimal luminal diameter (mm)
Before 0.73  0.38 0.72  0.41 0.82
After 1.99  0.47 2.70  0.46 0.0001
Follow-up 1.20  0.76 1.81  0.83 0.0001
Diameter stenosis (%)
Before 75  12 75  13 0.75
After 33  12 8  9 0.0001
Follow-up 61  23 38  25 0.0001
Acute gain (mm) 1.25  0.50 1.98  0.51 0.0001
Late loss (mm) 0.78  0.78 0.89  0.75 0.25
Net gain (mm) 0.47  0.73 1.08  0.82 0.0001
Diameter stenosis 50% at follow-up 82 (62%) 36 (27%) 0.0001
Total occlusion at follow-up 18 (13%) 5 (4%) 0.005
Data are presented as the mean value  SD or number (%) of patients.








(n  157) p Value
Infarct-related (1 month) lesion 77 (24%) 39 (25%) 38 (24%) 0.90
Previous PTCA at same site 64 (20%) 36 (23%) 28 (18%) 0.26
Site of angioplasty
RCA 96 (31%) 48 (31%) 48 (31%)
LAD 142 (45%) 71 (45%) 71 (45%) 1
LCx 60 (19%) 30 (19%) 30 (19%)
SVG 16 (5%) 8 (5%) 8 (5%) 
AHA/ACC classification
A 69 (22%) 42 (27%) 27 (17%)
B1 90 (29%) 44 (28%) 46 (29%) 0.22
B2 125 (40%) 57 (36%) 68 (43%)
C 30 (9%) 14 (9%) 16 (10%) 
TIMI flow grade
0 23 (7%) 11 (7%) 12 (8%)
1 10 (3%) 5 (3%) 5 (3%) 0.76
2 25 (8%) 10 (6%) 15 (9%)
3 256 (82%) 131 (83%) 125 (80%) 
Lesion length (mm) 8.6  4.2 8.4  3.8 8.8  4.7 0.42
Reference diameter (mm) 3.06  0.50 3.06  0.48 3.06  0.51 0.98
Minimal luminal diameter (mm) 0.73  0.39 0.74  0.38 0.72  0.40 0.76
Diameter stenosis (%) 75  13 75  13 76  13 0.72
Data are presented as the number (%) of patients or mean value  SD.
AHA/ACC  American Heart Association/American College of Cardiology; LAD  left anterior descending coronary
artery; LCx  left circumflex coronary artery; PTCA  percutaneous transluminal coronary angioplasty; RCA  right coronary
artery; SVG  saphenous vein graft; TIMI  Thrombolysis in Myocardial Infarction trial.
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nosis (0.8  11.3%; p  0.42). Because total occlusion of
dilated sites was frequent in BA patients, a significant
decrease in LVEF was observed in the entire BA group
(2.4 10.9%; p 0.02). Conversely, because occlusion of
dilated sites was quite rare in patients treated with coronary
stent implantation, no significant change in LVEF was
observed in the stent group (0.5  12.2%; p  0.60).
Clinical end points at four years. The actuarial rates of
clinical events are presented at four years. At this time point,
trends toward a lower total mortality rate (13.5% vs. 19.2%;
p 0.20), lower cardiac mortality rate (6.6% vs. 14.6%; p
0.07) (Fig. 1A), and lower rate of MI (9.9% vs. 16.0%; p 
0.06) (Fig. 1B) were observed in the stent group compared
with the BA group. The incidence of the composite end
point of cardiac death and non-fatal MI was significantly
lower in the stent group than in the BA group (14.8% vs.
26.0%; p  0.02) (Fig. 1C). Repeat revascularization
(PTCA or coronary artery bypass graft surgery) was per-
formed in 35.4% of patients in the stent group compared
with 52.1% in the BA group (p  0.001) (Fig. 1D). This
reduction reflected a lower rate of target vessel revascular-
ization in the stent group (21.0% vs. 40.6%; p  0.0002)
(Fig. 1E). The composite end point of cardiac death,
non-fatal MI, and repeat revascularization was significantly
lower in the stent group than in the BA group (41.2% vs.
63.1%; p  0.0001) (Fig. 1F).
In an attempt to elucidate whether the reduction in the
incidence of the composite end point of cardiac death and
non-fatal MI observed in the stent group was mainly related
to the reduction in restenosis, multivariate analysis (Cox
proportional hazards model) was performed in patients with
six-month angiographic follow-up. The technique of revas-
cularization (stent or balloon) and the restenosis status were
entered into the model. Restenosis was found to be the key
predictor of the composite end point of cardiac death and
non-fatal MI (restenosis vs. no restenosis: hazard ratio
[HR]  2.39, 95% confidence interval [CI]  1.32 to 4.35,
p  0.004; stent vs. balloon: HR  0.67, 95% CI  0.36 to
1.23, p  0.20).
DISCUSSION
The findings of the present study comparing coronary stent
implantation with standard BA in diabetic patients matched
for five major patient and lesion characteristics clearly
demonstrate that coronary stent implantation was associated
with a highly beneficial effect on both the six-month
angiographic outcome and four-year clinical events, com-
pared with standard BA, and strongly suggest that stent
implantation should be the preferred strategy when PCR is
performed in diabetic patients.
Previous studies. Restenosis in diabetic patients is consid-
ered to be related to enhanced neointimal hyperplasia (17),
an accelerated fibrotic response (18), and an enhanced
predisposition to vascular thrombosis (19). Previously pub-
lished studies have yielded conflicting results on the poten-
tial benefit of coronary stent implantation in diabetic pa-
tients. Data on angiographic outcomes are derived from
studies investigating the effect of diabetes on restenosis
either in patients treated with standard BA (4,9,10) or in
those treated with coronary stent implantation (11–14).
These studies included patients with differing clinical char-
acteristics, and they reported a wide range of restenosis rates
after BA (35% to 71%) (4,9,10) and stent implantation
(24% to 55%) (11–14). Carrozza et al. (11) reported a
restenosis rate of 55% in a population of diabetic patients
treated at a saphenous vein graft lesion in more than half of
cases, Elezi et al. (14) reported a restenosis rate of 37% in a
diabetic population in whom multiple overlapping-stenting
was common (44% of cases), while we previously reported
(12) a 24% restenosis rate in patients exclusively treated on
native coronary artery lesions and in whom multiple
overlapping-stenting was rare (20% of cases).
Data on clinical outcomes are even more difficult to
compare. Although extensive data on the 5- to 10-year
clinical outcomes of diabetic patients treated with standard
BA are available (1,2,5–7,20), data focused on the outcomes
of diabetic patients treated with coronary stenting are
limited (14,21,22).
Coronary stenting and angiographic outcome. The
present study is the first study that attempts to directly
compare the effects of stent implantation and standard BA
in diabetic patients undergoing PCR without any pharma-
cologic adjunct. The matching process, using five major
criteria (i.e., gender, anti-diabetic regimen, vessel location,
vessel size, MLD), allowed us to select a group of patients
treated with standard BA with characteristics very similar to
the group of patients treated with coronary stent implanta-
tion. These patients were optimal candidates for stent
implantation or BA: they were treated on relatively large
vessels (mean reference diameter of 3.06 mm) and short
lesions (9 mm in length) that were covered with a single
stent in the vast majority of cases (80%).
As illustrated by a higher net gain (1.08 vs. 0.47 mm) and
a lower restenosis rate (27% vs. 62%), coronary stent
implantation was associated with a better six-month angio-
graphic outcome, compared with BA, in our population of
diabetic patients. These results strengthen some trends that
were seen in a subgroup analysis of previous randomized
studies. Indeed, diabetic patients in the STent REStenosis
Study (STRESS I-II) trials (n  92) had a lower restenosis
rate after coronary stenting than after standard BA (24% vs.
60%) (23). Similarly, among diabetic patients receiving the
antiplatelet agent abciximab in the Evaluation of Platelet
IIb/IIIa Inhibitor for STENTing (EPISTENT) trial, those
randomized to coronary stenting had a higher net gain at six
months than those treated with BA (0.88 vs. 0.43 mm; p 
0.001) (24).
Additional information is provided by analysis of the
angiographic data of the present study. First, coronary stent
implantation reduces the rate of occlusive restenosis (4% vs.
13%) and partly prevents the deterioration of LV function
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Figure 1. Four-year Kaplan-Meier curves for cardiac mortality (A); myocardial infarction (MI) (B); the composite end point of cardiac death and non-fatal
MI (C); repeat revascularization (D); target vessel revascularization (E); and the composite end point of cardiac death, non-fatal MI, and repeat
revascularization (F).
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observed at six months in diabetics treated with BA.
Second, although the risk of occlusive or non-occlusive
restenosis may vary between subgroups, the beneficial effect
of coronary stent implantation is consistent among these
subgroups. Finally, this study also shows that stent implan-
tation is not a panacea for restenosis in diabetic patients.
Restenosis, particularly in its occlusive form, is still a major
concern when angioplasty is performed in SVG lesions,
small vessels (3.0 mm), long lesions (8.0 mm), or vessels
with TIMI flow grade 3.
Coronary stenting and clinical outcome. This study is the
first to demonstrate that the use of coronary stents may by
itself improve the long-term clinical outcome of diabetic
patients who have had PCR. Although the beneficial effect
of coronary stenting was partly related to a decreased need
for repeat revascularization (32% relative reduction), it is of
potentially greater clinical relevance that it was also associ-
ated with a 43% reduction in the combined end point of
cardiac death and MI at four years. The clinical benefit of
coronary stent implantation in diabetic patients, as reported
in the present study, is consistent with the recent observa-
tion of the EPISTENT trial, showing that among diabetics
receiving abciximab, those randomized to coronary stent
implantation had a trend toward a reduced rate of death and
large MI at one year compared with those treated with BA
(4.9% vs. 10.4%) (25). It is also consistent with the recently
reported outcome of the Arterial Revascularization Therapy
Study (ARTS) that compares stenting with coronary artery
bypass graft surgery in patients with multi-vessel coronary
artery disease (26) and shows that the mortality rate of
diabetic patients who have had stent implantation (7%) was
close to the mortality rate after bypass surgery (3%) and
much lower than the mortality rate observed two years after
BA in the Bypass Angioplasty Revascularization Investiga-
tion (BARI) trial (17%) (1).
When considered together, the angiographic and clinical
data in our study suggest that a lower rate of occlusive
restenosis and preserved LV function play key roles in the
reduction in the combined end point of cardiac death and
MI observed in patients treated with coronary stents. The
previous demonstration that occlusive restenosis is associ-
ated with a significant decrease in ejection fraction (4) and
poor long-term survival (27) in diabetic patients is also
consistent with this hypothesis.
Need for further improvement. We have to acknowledge,
however, that when used without pharmacologic adjunct,
the rate of clinical events remains high in diabetic patients
after coronary stent implantation. Elezi et al. (14) and
Abizaid et al. (21) recently reported a trend toward a higher
one-year mortality rate in diabetic patients than non-
diabetic patients after coronary stent implantation, and the
four-year mortality rate (13.5%) of diabetics treated with
coronary stents in our study also seems high compared with
the 9% mortality rate observed at three years by van
Domburg et al. (22) in a contemporary series of 1,000
unselected patients treated with coronary stents. This may
be partly explained by the persistently high rate of occlusive
restenosis seen in some subgroups of diabetics after coronary
stenting, as observed in the present study. In these sub-
groups of patients, coronary stenting should probably be
performed with concomitant glycoprotein IIb/IIIa block-
ade, as recently suggested by the analysis of the one-year
clinical follow-up of diabetic patients involved in the
EPISTENT trial (25). The relatively high rate of events
seen in diabetic patients after coronary stenting also war-
rants the need for more careful attention to secondary
prevention in these patients.
Study limitations. This was a single-center study, and
patient referral, technique of PTCA, and medical manage-
ment may have influenced the results. In addition, the high
rate of angiographic follow-up may have increased the target
lesion revascularization rate in our population, as recently
suggested by Ruygrok et al. (28). However, the combination
of a high rate of angiographic (85%) and clinical (100%)
follow-up allowed us to suggest a mechanism for the
reduced rate of cardiac death and MI observed in our study
after coronary stent implantation. Finally, it is evident that
this retrospective study based on matching does not have the
value of a randomized study. However, previous similar
studies based on matching (29,30) have accurately predicted
the results of prospective randomized trials (31–33).
Clinical implications. The present study demonstrates
that coronary stent implantation may provide a significant
benefit, compared with standard BA, in diabetic patients
and suggests that coronary stents, alone or in combination
with glycoprotein IIb/IIIa blockade, should be employed as
a standard therapy for PCR in this group of patients,
particularly when single-vessel revascularization needs to be
performed.
Because long-term survival of diabetic patients who need
multi-vessel revascularization is better after bypass surgery
than after standard BA (1,6,7,20), surgery is currently the
preferred revascularization technique in this group of pa-
tients. Our data, in conjunction with the data of the
EPISTENT and ARTS studies (26), suggest that modern
PCR with appropriate adjunctive pharmacotherapy (glyco-
protein IIb/IIIa blockade) may become a viable alternative
to bypass surgery in such patients. However, a prospective
randomized trial is required before such an approach can be
recommended in clinical practice. From this perspective, it
is worth noting that the preliminary results achieved with
drug-eluting stents (34) are encouraging.
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